C4 Therapeutics, Inc.
CCCC
$1.54
$0.042.67%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -34.57M | -24.67M | -17.72M | -28.36M | -34.75M |
| Total Depreciation and Amortization | 480.00K | 442.00K | 448.00K | 448.00K | 430.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | 0.00 |
| Total Other Non-Cash Items | 8.74M | 9.09M | 6.43M | 6.44M | 6.91M |
| Change in Net Operating Assets | 7.42M | -9.00M | 5.87M | 3.36M | 3.40M |
| Cash from Operations | -17.93M | -24.13M | -4.97M | -18.12M | -24.01M |
| Capital Expenditure | 4.00K | 13.00K | -197.00K | -- | -157.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 13.67M | 149.00K | -11.51M | -53.40M | 32.10M |
| Cash from Investing | 13.67M | 162.00K | -11.71M | -53.40M | 31.95M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 0.00 |
| Issuance of Common Stock | 111.00K | 10.29M | 135.00K | 34.61M | 57.67M |
| Repurchase of Common Stock | 0.00 | -85.00K | 0.00 | -109.00K | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1.00K | 297.00K | 0.00 | 84.00K | -1.00K |
| Cash from Financing | 112.00K | 10.51M | 135.00K | 34.58M | 57.67M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.15M | -13.47M | -16.55M | -36.93M | 65.61M |